MétaCan
Menu
Back to cohort
Record W2518731549

Comparison of physicochemical characteristics and stability of three novel formulations of paclitaxel: Abraxane, Nanoxel, and Genexol PM

2008· article· en· W2518731549 on OpenAlexaboutno aff
Niles Ron, Jon Cordia, Andrew Yang, Sherry Ci, Phithi Nguyen, Melissa Hughs, Neil Desai

Bibliographic record

VenueCancer Research · 2008
Typearticle
Languageen
FieldMedicine
TopicCancer Treatment and Pharmacology
Canadian institutionsnot available
Fundersnot available
KeywordsPaclitaxelDiluentChromatographyChemistryParticle sizeNuclear chemistryMedicineSurgeryChemotherapy
DOInot available

Abstract

fetched live from OpenAlex

5622 Background: Abraxane (Abraxis BioScience, Inc., Los Angeles, CA, approved in USA and Canada), Nanoxel (Dabur Pharma, H.P., India, approved in India), and Genexol PM (Samyang Pharmaceuticals, Seoul, Korea, approved in Korea) are 3 commercially approved, novel formulations of paclitaxel. Abraxane consists of albumin-bound injectable nanoparticles of paclitaxel, while Genexol and Nanoxel (utilizing cosolvents) are polymeric-micelle formulations. Abraxane and Genexol are lyophilized products approved for 25°C ± 2°C storage, while Nanoxel is a liquid formulation approved for 2-8°C storage. This study investigated the physicochemical characteristics and short-term stability of the 3 products under recommended clinical use conditions and under accelerated conditions.
 Methods: The drugs were reconstituted and prepared per the instructions provided in the respective package inserts. Abraxane and Genexol were reconstituted using the recommended saline diluent, while Nanoxel was mixed and diluted in 10% dextrose. Each drug was reconstituted to 0.7 mg/mL and 5 mg/mL. Physical stability was monitored both visually and microscopically; particle size was measured and monitored over time at room temperature (RT, measured to be 23°C) and 40°C using photon correlation spectroscopy (PCS) (Zetasizer 3000, Malvern, UK). Chemical purity was measured by reduced reversed-phase HPLC (Shimadzu Scientific Instruments, MD).
 Results: Following reconstitution, Abraxane was determined to be stable both physically and chemically at RT and 40°C over 24 hrs, with no evidence of nanoparticle size growth at either 0.7 mg/mL or 5 mg/mL. While reconstituted Genexol was stable at RT over 24 hrs, micelle instability resulting in precipitation of paclitaxel in the form of large needle-like crystals for both 0.7 mg/mL and 5 mg/mL formulations was seen between 2 to 4 hrs at 40°C. These observations were confirmed using orthogonal techniques, visual assessment from photomicrographs, and PCS particle size measurement. For Nanoxel at 0.7 mg/mL, a minor, but consistent, increase in particle size was observed at RT over 24 hrs. However, significant aggregation, particle-size growth, and crystallization were seen within 4 hrs at 40°C. HPLC data comparing pre- and post-filtration confirmed that the crystal formation for both Nanoxel and Genexol resulted from paclitaxel precipitation and aggregation. In addition, analytical results showed that Nanoxel had slightly lower paclitaxel purity as compared to either Abraxane or Genexol.
 Conclusions: Nanoparticle albumin-bound paclitaxel, Abraxane, showed excellent physicochemical stability as compared to the micellar formulations, Nanoxel and Genexol. Particle size growth and crystal formation were readily apparent in Nanoxel and Genexol, especially in the short term under accelerated conditions.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.264
GPT teacher head0.490
Teacher spread0.225 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations8
Published2008
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicCancer Treatment and PharmacologyFrench-language works237,207